Table 4.
Factors associated with overall survival in 62 patients with hepatocellular carcinoma who underwent evaluable radiological imaging
| Character | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
|
|
|
||||
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (year) | 0.985 (0.947-1.024) | .452 | |||
| Sex | Female vs male | 2.171 (0.497-9.479) | .303 | ||
| Alcohol | No vs yes | 1.237 (0.505-3.032) | .642 | ||
| HBV | No vs yes | 0.754 (0.338-1.679) | .489 | ||
| HCV | No vs yes | 0.891 (0.333-2.380) | .817 | ||
| Grade 1-2 irAEs | No vs yes | 1.786 (0.737-4.331) | .199 | ||
| Grade ≥3 irAEs | Yes vs no | 1.005 (0.373-2.710) | .992 | ||
| TTV (cm3) | ≤1000 vs >1000 | 3.500 (1.545-7.929) | .003 | ||
| Tumor number | Single vs multiple | 3.355 (0.996-11.302) | .051 | ||
| MVI | No vs yes | 3.222 (1.343-7.733) | .009 | ||
| EHM | No vs yes | 1.020 (0.451-2.304) | .962 | ||
| CLIP score | 0-2 vs ≥3 | 4.333 (1.811-10.367) | .001 | 3.257 (1.349-7.866) | .009 |
| AFP (ng/mL) | <400 vs ≥400 | 1.721 (0.779-3.800) | .179 | ||
| NLR | ≤3.0 vs >3.0 | 9.543 (1.282-71.038) | .028 | ||
| AST (U/L) | ≤40 vs >40 | 1.354 (0.456-4.014) | .585 | ||
| ALT (U/L) | ≤40 vs >40 | 2.571 (1.066-6.204) | .036 | ||
| Child-Pugh class | A vs B/C | 2.152 (0.960-4.826) | .063 | ||
| ALBI grade | 1 vs 2/3 | 11.028 (1.476-82.406) | .019 | ||
| Prior therapy | |||||
| Sorafenib | No vs yes | 1.476 (0.672-3.241) | .332 | ||
| Lenvatinib | No vs yes | 2.059 (0.808-5.2247) | .130 | ||
| Concurrent therapy | No vs yes | 0.611 (0.270-1.383) | .237 | ||
| TKI | No vs yes | 0.730 (0.336-1.585) | .426 | ||
| TACE | No vs yes | 0.302 (0.071-1.295) | .107 | ||
| RT | No vs yes | 1.515 (0.486-4.721) | .473 | ||
| AFP response | Yes vs no | 1.369 (0.600-3.124) | .455 | ||
| Best response | CR + PR vs none | 3.402 (1.160-9.982) | .026 | ||
AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIP, Cancer of the Liver Italian Program; CR + PR, complete response plus partial response; EHM, extrahepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; irAEs, immune-related adverse events; MVI, macroscopic vascular invasion; NLR, neutrophil-lymphocyte ratio; RT, radiotherapy; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TTV, total tumor volume.